The bottomline, meanwhile, enjoyed a one-off lift from the recognition of a previously unrecognised deferred tax asset by Acibadem Holdings, IHH’s Turkey operations.
“Performance continued to rebound as patients returned to our hospital services network, and as we continue to prioritise Covid-19 support to help governments in some of our countries,” says managing director and CEO Dr Kelvin Loh.
He adds that the company’s efforts to optimise its capital structure and operations have started to pay off. Gleneagles Hong Kong Hospital delivered a positive EBITDA in the third quarter, while Turkey and India operations have recovered fully and are geared for continued expansion.
“Our growth from here will be driven both organically and inorganically,” says Loh.
See also: Keppel Pacific Oak US REIT’s 1QFY2025 distributable income falls by 19.3% y-o-y to US$9.6 mil
“We are also making innovation investments as part of our digital transformation roadmap to seize disruptive opportunities that will give patients better, faster and affordable care,” he adds.
IHH, traded on both the Malaysia and Singapore bourses, closed Nov 29 at RM6.60 and $2.12 respectively.
Photo of Mount Elizabeth Novena by The Edge Singapore
